Upstream Bio, Stock Working Capital
| UPB Stock | 19.19 0.26 1.34% |
Upstream Bio, fundamentals help investors to digest information that contributes to Upstream Bio,'s financial success or failures. It also enables traders to predict the movement of Upstream Stock. The fundamental analysis module provides a way to measure Upstream Bio,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Upstream Bio, stock.
As of December 28, 2024, Net Working Capital is expected to decline to about 68.2 M. The current year's Change In Working Capital is expected to grow to about (4.1 M). Upstream |
Upstream Bio, Company Working Capital Analysis
Upstream Bio,'s Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Upstream Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Upstream Bio, is extremely important. It helps to project a fair market value of Upstream Stock properly, considering its historical fundamentals such as Working Capital. Since Upstream Bio,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Upstream Bio,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Upstream Bio,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
As per the company's disclosures, Upstream Bio, has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The working capital for all United States stocks is 100.0% higher than that of the company.
Upstream Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Upstream Bio,'s direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Upstream Bio, could also be used in its relative valuation, which is a method of valuing Upstream Bio, by comparing valuation metrics of similar companies.Upstream Bio, is currently under evaluation in working capital category among its peers.
About Upstream Bio, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Upstream Bio,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Upstream Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Upstream Bio, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Upstream Bio, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio, Stock:Check out Upstream Bio, Piotroski F Score and Upstream Bio, Altman Z Score analysis. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio,. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Upstream Bio, is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio,'s market value can be influenced by many factors that don't directly affect Upstream Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.